OTCMKTS:PBIO Pressure BioSciences (PBIO) Stock Price, News & Analysis $0.0045 0.00 (0.00%) As of 04/3/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsSEC FilingsShort InterestBuy This Stock About Pressure BioSciences Stock (OTCMKTS:PBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pressure BioSciences alerts:Sign Up Key Stats Today's Range$0.0045▼$0.004550-Day Range$0.0036▼$0.013552-Week Range$0.00▼$0.31VolumeN/AAverage Volume7,616 shsMarket Capitalization$193,351.50P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.Read More… Remove Ads Pressure BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScorePBIO MarketRank™: Pressure BioSciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pressure BioSciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pressure BioSciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pressure BioSciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Pressure BioSciences has been sold short.Short Interest Ratio / Days to CoverPressure BioSciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPressure BioSciences does not currently pay a dividend.Dividend GrowthPressure BioSciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the float of Pressure BioSciences has been sold short.Short Interest Ratio / Days to CoverPressure BioSciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media2.0 / 5News SentimentN/A News SentimentPressure BioSciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pressure BioSciences this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pressure BioSciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.80% of the stock of Pressure BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.02% of the stock of Pressure BioSciences is held by institutions.Read more about Pressure BioSciences' insider trading history. Receive PBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PBIO Stock News HeadlinesPressure BioSciences (OTCMKTS:PBIO) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedApril 3 at 2:51 AM | americanbankingnews.comPressure BioSciences Partners with Vita-Forte, Largest Global Supplier of Freeze-Dried Acai, to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral SprayJune 25, 2024 | globenewswire.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.April 4, 2025 | Porter & Company (Ad)Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ETJune 18, 2024 | globenewswire.comPressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ETJune 13, 2024 | globenewswire.comThe big blood pressure experimentApril 24, 2024 | bbc.co.ukPacBio moved to Neutral at JPMorgan after guidance cutApril 22, 2024 | msn.comPressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”April 2, 2024 | finance.yahoo.comSee More Headlines PBIO Stock Analysis - Frequently Asked Questions How have PBIO shares performed this year? Pressure BioSciences' stock was trading at $0.0035 at the beginning of the year. Since then, PBIO stock has increased by 28.6% and is now trading at $0.0045. View the best growth stocks for 2025 here. How were Pressure BioSciences' earnings last quarter? Pressure BioSciences, Inc. (OTCMKTS:PBIO) released its quarterly earnings results on Friday, February, 7th. The company reported ($0.15) EPS for the quarter. How do I buy shares of Pressure BioSciences? Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pressure BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pressure BioSciences investors own include Hydrofarm Holdings Group (HYFM), Advanced Micro Devices (AMD), Monaker Group (MKGI), Meta Materials (MMAT), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP) and Novavax (NVAX). Company Calendar Last Earnings2/07/2025Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolOTCMKTS:PBIO CIK830656 Webwww.pressurebiosciences.com Phone508-230-1828Fax508-230-1829Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,310,000.00 Net Margins-2,053.81% Pretax Margin-2,053.68% Return on EquityN/A Return on Assets-743.79% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.01 Sales & Book Value Annual Sales$1.98 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($1.29) per share Price / Book0.00Miscellaneous Outstanding Shares42,967,000Free Float36,543,000Market Cap$193,351.50 OptionableNot Optionable Beta-0.41 Social Links Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (OTCMKTS:PBIO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pressure BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pressure BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.